Paradigm Capital set a $8.50 price objective on OrganiGram (NASDAQ:OGI) in a research note issued to investors on Thursday morning, TipRanks reports. The firm currently has a buy rating on the stock.
OGI has been the topic of several other reports. Raymond James initiated coverage on shares of OrganiGram in a research note on Wednesday, September 18th. They issued a buy rating on the stock. Jefferies Financial Group upgraded shares of OrganiGram from a hold rating to a buy rating and set a $8.20 target price on the stock in a research note on Friday, October 11th. Zacks Investment Research upgraded shares of OrganiGram from a hold rating to a buy rating and set a $4.00 target price on the stock in a research note on Thursday. Oppenheimer initiated coverage on shares of OrganiGram in a research note on Thursday, September 5th. They issued a market perform rating on the stock. Finally, Pi Financial set a $12.00 target price on shares of OrganiGram and gave the stock a buy rating in a research note on Monday, July 15th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company has an average rating of Buy and an average price target of $8.34.
NASDAQ OGI traded down $0.13 on Thursday, hitting $3.60. The stock had a trading volume of 2,070,365 shares, compared to its average volume of 2,055,533. OrganiGram has a 52-week low of $2.71 and a 52-week high of $8.44. The business has a 50-day moving average of $3.93.
OrganiGram Company Profile
OrganiGram Holdings Inc, through its subsidiaries, produces and sells dried cannabis and cannabis oil in Canada. It also offers wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis oils to retailers and wholesalers. The company also exports its products. It sells its products online, as well as through phone orders.
Featured Story: Momentum Investing
Receive News & Ratings for OrganiGram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrganiGram and related companies with MarketBeat.com's FREE daily email newsletter.